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Is it important to consider sex and gender in neurocognitive, neurobiological, and clinical stud-
ies? I refer here to “sex” as a biological variable related mainly to sex chromosomes and sex
steroid hormones, while “gender” stands for a psychosociocultural construct related to gender
role socialization, levels of masculinity and femininity, and stress related to adhesion to gen-
der stereotypes. It is a rhetorical question and I hope that an overwhelming majority of read-
ers would answer: “yes, of course!” However, despite the fact that more attention has been
devoted over the past decade to delineating differences between men and women in their neu-
roanatomy, neurophysiology, and cognitive and emotional processing (1, 2), a substantial num-
ber of researchers (basic and clinical) continue ignoring “the second sex” and study exclusively
males. The reasons are multiple and range from an unawareness, through a lack of sufficient
funding to examine both sexes, to the argument that the studies, to date, have not found any
significant sex differences in a given paradigm or disorder and therefore there is no need to
include both males and females in a study. Finally, there is a group of theorists who sees this
line of inquiry (i.e., investigating sex differences in the brain and cognition) as inherently biased,
thus contributing to some harmful stereotypes that may lead to increasing gender inequalities
[e.g., Ref. (3, 4)].
It is hard to argue with the lack of funds and indeed there are cognitive and clinical domains where
we have not seen any indication of potential sex or gender differences. Nevertheless, our technology
has improved and we possess more sensitive instrumentation, which may detect subtle differences
that were not previously apparent. Moreover, we must remember that men and women of today are
different from men and women of two or three decades ago. We are not only socialized differently,
due to changed family values and education, more competitive job market and prominence of
social media, but also exposed tomore environmental toxins, including endocrine disruptors, which
may affect our physical and mental health (5, 6). As to the harmful effects of some studies of the
neurobiological and cognitive sex differences, I agree that data are sometimes interpreted in a biased
manner andmay contribute to propagation of damaging gender stereotypes. However, I also believe
that excluding women is much more dangerous. We have seen the harm done with several drugs
released for treatment of various disorders without proper testing or consideration of women’s
physiology (e.g., Posicor, approved for the treatment of hypertension and angina, slowed or stopped
the heart rate especially in elderly women; antihistamines such as Seldane and Hismanal induced
cardiac arrhythmias disproportionally more frequently in women), but thankfully the situation is
changing (7, 8).
While it is true that men and women are much more alike than different and it actually
makes more sense to talk about sex and gender similarities (be it in brain structure or cognitive
function), there are those subtle differences that may provide clues to disentangling etiology of some
neurological and neuropsychiatric disorders, such as multiple sclerosis, autism, mood, and anxiety
disorders, or shed a new light on treatment of these conditions. In short, “vive la similarité, but
let’s explore differences!” I would like to use two clinical examples that I am most familiar with, to
illustrate my point – schizophrenia and drug addiction.
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Schizophrenia
The existence of sex differences in the prevalence, development,
and progression of schizophrenia was noted already by Kraepelin
and Bleuler who conceptualized and meticulously described the
disorder at the beginning of the twentieth century (9, 10). Possibly
because the prevalence of schizophrenia is greater in men than in
women during the first half of life (until about 40 years of age),
most studies forgot about women altogether – this despite the fact
that there is a second peak of new cases in women around the
age of menopause when they catch up with men in the prevalence
(11, 12). I was unaware of this bias when I started investigating
neural correlates of cognitive function in schizophrenia during
my graduate school years, but very soon afterwards, as an inde-
pendent researcher, it became clear that existing theories and
treatment of schizophrenia were based almost entirely on data
from male subjects (human and animal). This realization hit me
when I came across two intriguing research studies, which found
a neuroanatomical reversal of normal sexual dimorphism in the
anterior cingulate (13), amygdala, and orbitofrontal cortex (OFC)
(14). Due to my research familiarity with functional magnetic
resonance imaging (fMRI), I began to search for any fMRI stud-
ies of emotion processing in schizophrenia since the anterior
cingulate, amygdala, and OFC are all part of the corticolimbic
system heavily implicated in the experience and expression of
affect. I found numerous studies that met my search criteria, but
none of them examined sex differences as they included either
exclusively men, or the number of women was too small to allow
for any comparisons. This was almost a decade ago and it has
motivated our group to make an extra effort to recruit women
diagnosed with schizophrenia to our studies. We have conducted
several fMRI studies; some revealed reversal of normal sexual
dimorphism [e.g., during mental rotation task; (15)], others did
not find any sex or sex-specific differences [e.g., during passive
viewing of emotional stimuli; (16)], while a few found significant
relationship between brain activations and sex steroid hormones
[e.g., Ref. (17, 18)]. This line of research suggested to us that
there might be a subtype of schizophrenia patients where symp-
toms and related brain dysfunction is partly fostered by hor-
monal imbalance during organizational and/or activational stage
of neurodevelopment.
Thankfully, over the past decade the situation in the field
has changed; sex differences in schizophrenia are more widely
acknowledged and females (both animal and human) are more
frequently studied or at least included in the protocols. It is also
recognized thatwomenmight require lower doses of antipsychotic
medications during their reproductive years (due to interactions
between antipsychotic medications and estradiol) and that they
may benefit from low doses of estradiol or selective estrogen
receptor modulators (SERMs) (19). It is possible that factors con-
tributing to the development of schizophrenia and related psy-
chosis are slightly different inmen andwomenor that these factors
interact differently with the sexes. For example, perturbation in
the organizational effects of testosterone in utero could affect
male and female fetuses differently, and exposure to environmen-
tal toxins could affect endocrine systems of males and females
differently.
Drug Addiction
Drug addiction is another condition characterized by important
differences between men and women, and demonstrates how
research has changed over the past few decades. Somewhat sim-
ilarly to schizophrenia, traditionally drug abuse and dependence
have been considered a “male problem.” However, while the
prevalence of alcohol and cannabis dependence is still greater
among men, gender differences in the abuse of stimulants and
prescription drugs seem to have disappeared in theWestern world
(20). In addition, women appear to be more prone to develop
drug dependence, suffer more severe physical and psychologi-
cal consequences of drug abuse, and have a more difficult time
“kicking the habit” (21). The reasons for this gender gap include
a mixture of biological and psychosocial factors. For example,
while a larger proportion of men initiate drug use to induce
feelings of elation, energy or focus, women frequently start taking
drugs to alleviate pre-existing mental health problems, including
depression and anxiety (22). This maladaptive self-medication
strategy often results in a faster transition to a habitual drug use
and eventually a more severe dependence (23, 24). In addition,
the socio-cultural norms, particularly in theWestern society, have
changed dramatically over the past few decades. Thus, while there
is still a more severe stigma and prejudice against women who
use drugs, especially if they are pregnant or have children, overall
there is greater acceptance of women’s drug use than it was several
decades ago (25). Moreover, women have much greater access to
various drugs of abuse than they used to have. Finally, over the
past couple of decades, new research has suggested some neuro-
biological factors that could also contribute to sex differences in
drug addiction. For example, there is evidence that the dopamine
system, which for decades has been strongly implicated in drug
reinforcement, is sexually dimorphic. The number of dopaminer-
gic neurons, the density of the dopaminergic terminals, as well as
responsiveness of the dopaminergic system to drugs of abuse, have
been shown to differ between males and females and they have
been shown to be modulated by sex steroid hormones, especially
estrogen (22, 26, 27). All these psychological, socio-cultural, and
biological factors that contribute to sex differences in drug use
and drug dependence should be considered while evaluating and
treating individuals with drug addiction problems.
Our research has focused specifically on addiction to nicotine
partly because it is a significant problem in schizophrenia. In the
general population, still more men than women smoke cigarettes,
but this gap is decreasing steadily. Moreover, studies show that
women become dependent faster and have more difficulties quit-
ting the habit thanmen (28). The difficulty quitting and the higher
relapse rates have been linked to greater levels of drug craving,
although evidence is still equivocal. For example, we examined
sex differences in cue-induced craving for cigarettes in non-
deprived smokers and did not find any differences between men
andwomen (29). Therewere, however, fluctuations in the craving-
related fMRI activations across the menstrual cycle in women.
I should highlight that in our study we tested only non-deprived
smokers, while studies that have reported sex differences, typically
assessed craving following a period of abstinence [e.g., Ref. (30,
31)]. Indeed, some studies suggest that men are more sensitive
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to cue-induced craving, while women react stronger to stress-
induced craving [e.g., Ref. (32)]. These and similar studies may
be helpful in developing gender-sensitive treatment programs.
I presented just two examples of neuropsychiatric problems
where unraveling sex differences may benefit women and deepen
our understanding of the disorders. For instance, several promis-
ing clinical trials have already been performed with low doses
of estradiol to treat women and men with schizophrenia (19,
33). In terms of drug addiction, most rehabilitation programs
are still based on a male model, but it is recognized that
women may require additional support (e.g., family planning,
childcare services) and approaches that emphasize stress reduc-
tion (34).
Before closing I would like to mention gender, feminin-
ity/masculinity and related variables, which have been almost
entirely absent from the neuroscience research, with a few excep-
tions. For example, in one early study, Cahill et al. (35) demon-
strated that although no differences were detected between sexes
in emotional memory, when gender was taken into consider-
ation, individuals with more masculine traits showed superior
recall of central emotional information, whereas individuals with
more feminine traits exhibited better recall of peripheral details.
More recent neuroanatomical studies reveal comparable results.
Thus, a study in healthy adults showed that identification with
more feminine traits correlated with greater straight gyrus volume
(part of the ventral frontal cortex) and with better performance
on a social cognition task [interpersonal perception task; (36)].
A different study, in children, reported that higher masculinity
predicted greater volumes ofwhitematter in the frontal lobe, while
higher femininity predicted greater volumes of gray matter in the
temporal lobe (37). These studies point to the possibility that even
though sex and gender are closely related, in some situations,
gender differences may be more important than sex differences
and thus both should be studied in human participants. However,
we need better gendermeasures, asmany tests and questionnaires,
such as the popular Bem Sex Role Inventory (38) were developed
in 1970s.
To conclude, neurocognitive, neurobiological, and clinical
studies that do not include female participants (animal or human)
present only half of the story, the male part. In some cases, this
may not be a problem, but in many it can deter us from scientific
progress in understanding etiology, and in developing successful
treatments for neurological and neuropsychiatric disorders in
men and women. Studies that do not include females are only
half-truth, and as Cahill (39) so eloquently stated using a Yiddish
proverb – “A half-truth is a whole lie.”
References
1. Bao AM, SwaabDF. Sex differences in the brain, behavior, and neuropsychiatric
disorders. Neuroscientist (2010) 16(5):550–65. doi:10.1177/1073858410377005
2. McCarthy MM, Arnold AP, Ball GF, Blaustein JD, De Vries GJ. Sex differences
in the brain: the not so inconvenient truth. J Neurosci (2012) 32(7):2241–7.
doi:10.1523/JNEUROSCI.5372-11.2012
3. Eagly AH, Riger S. Feminism and psychology: critiques of methods and episte-
mology. Am Psychol (2012) 69(7):685–702. doi:10.1037/a0037372
4. Eagly AH, Eaton A, Rose SM, Riger S,McHughMC. Feminism and psychology:
analysis of a half-century of research on women and gender. Am Psychol (2014)
67(3):211–30. doi:10.1037/a0027260
5. Chevalier N, Fénichel P. Endocrine disruptors: new players in the pathophys-
iology of type 2 diabetes? Diabetes Metab (2015) 41(2):107–15. doi:10.1016/j.
diabet.2014.09.005
6. Frye CA. Endocrine-disrupting chemicals: elucidating our understanding of
their role in sex and gender-relevant end points. Vitam Horm (2014) 94:41–98.
doi:10.1016/B978-0-12-800095-3.00003-1
7. Chilet-Rosell E.Gender bias in clinical research, pharmaceuticalmarketing, and
the prescription of drugs. Glob Health Action (2014) 9(7):25484. doi:10.3402/
gha.v7.25484
8. Poon R, Khanijow K, Umarjee S, Fadiran E, Yu M, Zhang L, et al. Participation
of women and sex analyses in late-phase clinical trials of new molecular entity
drugs and biologics approved by the FDA in 2007-2009. J Womens Health
(Larchmt) (2013) 22(7):604–16. doi:10.1089/jwh.2012.3753
9. Bleuler E. Dementia Praecox or the Group of Schizophrenias. London: George
Allen & Unwin (1911/1950).
10. Kraepelin E, Barclay RM, Robertson GM. Dementia Praecox and Paraphrenia.
Livingstone: Edinburgh (1919).
11. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev
Psychiatry (2010) 22(5):417–28. doi:10.3109/09540261.2010.515205
12. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature.
Acta Psychiatr Scand Suppl (2000) 401:3–38. doi:10.1111/j.0065-1591.2000.
0ap25.x
13. Goldstein JM, Seidman LJ, O’Brien LM, Horton NJ, Kennedy DN, Makris N,
et al. Impact of normal sexual dimorphisms on sex differences in structural
brain abnormalities in schizophrenia assessed by magnetic resonance imaging.
Arch Gen Psychiatry (2002) 59(2):154–64. doi:10.1001/archpsyc.59.2.154
14. Gur RE, Kohler C, Turetsky BI, Siegel SJ, Kanes SJ, Bilker WB, et al. A sexually
dimorphic ratio of orbitofrontal to amygdala volume is altered in schizophrenia.
Biol Psychiatry (2004) 55(5):512–7. doi:10.1016/j.biopsych.2003.10.009
15. Jiménez JA, Mancini-Marïe A, Lakis N, Rinaldi M, Mendrek A. Disturbed
sexual dimorphism of brain activation duringmental rotation in schizophrenia.
Schizophr Res (2010) 122(1–3):53–62. doi:10.1016/j.schres.2010.03.011
16. Lakis N, Jiménez JA, Mancini-Marïe A, Stip E, Lavoie ME, Mendrek A. Neural
correlates of emotional recognitionmemory in schizophrenia: effects of valence
and arousal. Psychiatry Res (2011) 194(3):245–56. doi:10.1016/j.pscychresns.
2011.05.010
17. Champagne J, Lakis N, Bourque J, Stip E, Lipp O, Mendrek A. Progesterone
and cerebral function during emotion processing in men and women with
schizophrenia. Schizophr Res Treatment (2012) 2012:917901. doi:10.1155/2012/
917901
18. Mendrek A, Bourque J, Dubé A, Lakis N, Champagne J. Emotion processing
in women with schizophrenia is menstrual cycle phase and affective valence
dependent: an FMRI study. ISRN Psychiatry (2012) 1(2012):656274. doi:10.
5402/2012/656274
19. Kulkarni J, Hayes E, Gavrilidis E. Hormones and schizophrenia. Curr Opin
Psychiatry (2012) 25(2):89–95. doi:10.1097/YCO.0b013e328350360e
20. Cotto JH, Davis E, Dowling GJ, Elcano JC, Staton AB, Weiss SR. Gender
effects on drug use, abuse, and dependence: a special analysis of results from
the National Survey on Drug Use and Health. Gend Med (2010) 7(5):402–13.
doi:10.1016/j.genm.2010.09.004
21. Fattore L, Altea S, Fratta W. Sex differences in drug addiction: a review of
animal and human studies. Womens Health (Lond Engl) (2008) 4(1):51–65.
doi:10.2217/17455057.4.1.51
22. Becker JB, Perry NB,Westenbroek C. Sex differences in the neural mechanisms
mediating addiction: a new synthesis and hypothesis. Biol Sex Differ (2012)
3(1):3–14. doi:10.1186/2042-6410-3-14
23. LynchWJ. Sex differences in vulnerability to drug self-administration. Exp Clin
Psychopharmacol (2006) 14(1):34–41. doi:10.1037/1064-1297.14.1.34
24. Becker JB, Hu M. Sex differences in drug abuse. Front Neuroendocrinal (2008)
29(1):36–47. doi:10.1016/j.yfrne.2007.07.003
25. Kandall SR. Women and drug addiction: a historical perspective. J Addict Dis
(2010) 29(2):117–26. doi:10.1080/10550881003684491
26. Fattore L, Melis M, Fadda P, Fratta W. Sex differences in addictive disorders.
Front Neuroendocrinol (2014) 35(3):272–84. doi:10.1016/j.yfrne.2014.04.003
Frontiers in Psychiatry | www.frontiersin.org June 2015 | Volume 6 | Article 833
Mendrek Sex and gender in clinical neuroscience
27. Moran-Santa Maria MM, Flanagan J, Brady K. Ovarian hormones and drug
abuse. Curr Psychiatry Rep (2014) 16(11):511. doi:10.1007/s11920-014-0511-7
28. Lombardi EM, Prado GF, Santos Ude P, Fernandes FL. Women and smoking:
risks, impacts, and challenges. J Bras Pneumol (2011) 37:118–28. doi:10.1590/
S1806-37132011000100017
29. Mendrek A, Dinh-Williams L, Bourque J, Potvin S. Sex differences and men-
strual cycle phase-dependent modulation of craving for cigarette: an fMRI pilot
study. Psychiatry J (2014) 2014:723632. doi:10.1155/2014/723632
30. Leventhal AM, Waters AJ, Boyd S, Moolchan ET, Lerman C, Pickworth WB.
Gender differences in acute tobaccowithdrawal: effects on subjective, cognitive,
and physiological measures. Exp Clin Psychopharmacol (2007) 15(1):21–36.
doi:10.1037/1064-1297.15.1.21
31. Xu J, Azizian A, Monterosso J, Domier CP, Brody AL, Fong TW, et al.
Gender effects on mood and cigarette craving during early abstinence and
resumption of smoking. Nicotine Tob Res (2008) 10(11):1653–61. doi:10.1080/
14622200802412929
32. Potenza MN, Hong KI, Lacadie CM, Fulbright RK, Tuit KL, Sinha R. Neural
correlates of stress-induced and cue-induced drug craving: influences of sex and
cocaine dependence. Am J Psychiatry (2012) 169(4):406–14. doi:10.1176/appi.
ajp.2011.11020289
33. Kulkarni J, Gavrilidis E, Worsley R, Van Rheenen T, Hayes E. The role of
estrogen in the treatment of men with schizophrenia. Int J Endocrinol Metab
(2013) 11(3):129–36. doi:10.5812/ijem.6615
34. Gopman S. Prenatal and postpartum care of women with substance use dis-
orders. Obstet Gynecol Clin North Am (2014) 41(2):213–28. doi:10.1016/j.ogc.
2014.02.004
35. Cahill L, Gorski L, Belcher A, Huynh Q. The influence of sex versus sex-
related traits on long-term memory for gist and detail from an emotional story.
Conscious Cogn (2004) 13:391–400. doi:10.1016/j.concog.2003.11.003
36. Wood JL, Heitmiller D, Andreasen NC, Nopoulos P. Morphology of the ventral
frontal cortex: relationship to femininity and social cognition. Cereb Cortex
(2008) 18(3):534–40. doi:10.1093/cercor/bhm079
37. Belfi AM, Conrad AL, Dawson J, Nopoulos P. Masculinity/femininity pre-
dicts brain volumes in normal healthy children. Dev Neuropsychol (2014)
39(1):25–36. doi:10.1080/87565641.2013.839681
38. Bem SL. Gender schema theory: a cognitive account of sex typing. Psychol Rev
(1981) 88:354–61. doi:10.1037/0033-295X.88.4.354
39. Cahill L. A half-truth is a whole lie: on the necessity of investigating sex
influences on the brain. Endocrinology (2012) 153(6):2541–3. doi:10.1210/en.
2011-2167
Conflict of Interest Statement: The author declares that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Mendrek. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordancewith
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Psychiatry | www.frontiersin.org June 2015 | Volume 6 | Article 834
